Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2014 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Other Non-Current Liabilities of $2.9 million for Q1 2026, down 15.85% year-over-year from $3.4 million in Q1 2025, and up 98.34% quarter-over-quarter from $1.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Other Non-Current Liabilities for 7 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 15.85% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 15.85% YoY), while the FY2025 annual figure was $1.4 million, down 74.45% from the prior year.
- Other Non-Current Liabilities climbed to $2.9 million in Q1 2026 per GYRE's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $10.8 million in Q3 2024 and bottomed at $47000.0 in Q2 2024.
- Historically, Other Non-Current Liabilities has averaged $3.8 million across 4 years, with a median of $3.2 million in 2025.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 11467.35% in 2024 and fell as far as 99.5% in 2024.
- Gyre Therapeutics' Other Non-Current Liabilities stood at $49000.0 in 2023, then soared by 11467.35% to $5.7 million in 2024, then slumped by 74.45% to $1.4 million in 2025, then surged by 98.34% to $2.9 million in 2026.
- Business Quant data shows GYRE's Other Non-Current Liabilities at $2.9 million in Q1 2026, $1.4 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.74 Mn |
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 3.22 Mn |
| Jun 30, 2025 | 3.20 Mn |
| Mar 31, 2025 | 3.41 Mn |
| Dec 31, 2024 | 5.67 Mn |
| Sep 30, 2024 | 10.76 Mn |
| Jun 30, 2024 | 47,000.00 |
| Mar 31, 2024 | 48,000.00 |
| Dec 31, 2023 | 49,000.00 |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 4.61 Mn |
| Mar 31, 2023 | 9.55 Mn |
| Sep 30, 2016 | 28,000.00 |
| Jun 30, 2016 | 130,000.00 |
| Mar 31, 2016 | 196,000.00 |
| Dec 31, 2015 | 1.16 Mn |
| Sep 30, 2015 | 676,000.00 |
| Dec 31, 2014 | 391,000.00 |